Antigen Design and Antibody Discovery
MyD88-specific antigens are selected, and antibodies are generated using various immunization strategies, followed by high-throughput screening to identify binding candidates.
Solutions
Online Inquiry
Monoclonal Antibodies Development
The MyD88 signalling pathway is crucial in managing multiple diseases, including inflammatory, autoimmune, infectious, and cancerous diseases. One type of therapeutic agent that is highly effective in treating diseases is monoclonal antibodies. Protheragen is a research service provider that offers one-stop services for the development of monoclonal antibodies aimed at MyD88.
Monoclonal Antibodies of MyD88
Monoclonal antibodies targeting MyD88 primarily aim to block its interactions with upstream and downstream signaling molecules. These antibodies, such as specific anti-MyD88 monoclonal antibodies, bind to the TIR domain of MyD88, preventing its dimerization and subsequent activation of downstream inflammatory pathways. Unlike small molecule inhibitors, monoclonal antibodies provide high specificity and the potential for targeted immune modulation. They are being explored for therapeutic applications in autoimmune diseases, chronic inflammation, and cancers that rely on MyD88-mediated signaling for tumor growth and progression.
Fig.1 MyD88 Signaling Leads to Cell Specific Functions in Cardiovascular Disease. (Bayer and Alcaide, 2021)Mechanism of MyD88-Targeting Monoclonal Antibodies
From the standpoint of monoclonal antibody therapy, MyD88 targeting therapeutics aim to modify the innate immune functions of the body on a molecular level by means of specific actions. Such approaches utilize the function of MyD88 in signal transduction for the purpose of achieving certain therapeutic objectives.
Molecular Intervention Mechanisms
These MyD88 binding antibodies technically act upon certain MyD88 domains, which because of morphologic changes of crucial signalling complexes that they are able to hinder, and even distal signalling, that they disrupt along with antibody structure and efficiency, hence are well capable of therapeutic goals.
Target Recognition and Binding Specificity
The selection and optimization of epitopes lead to MyD88-targeting antibodies which are binding target-specific. Structural biology delineation of binding sites renders free antibodies to be more targeted and less "on" and "off" side effects which is very important because MyD88's function is in signalling.
Our Services
Protheragen works on creating monoclonal antibodies directed to MyD88 at the latest R&D platforms. Our company is engaged in all preclinical stages of development of the drug which makes it possible to accelerate the creation of new MyD88 associated antibody therapeutics.
Workflow of MyD88-Targeted Monoclonal Antibody Development
Antibody Optimization
Antibodies are optimized for higher affinity and stability, ensuring effective blockade of MyD88 signaling through detailed bioassays.
Preclinical Research
Pharmacokinetic, pharmacodynamic, and safety studies are conducted to evaluate the antibody's suitability for clinical use.
Clinical Research Support
Support is provided for Investigator-Initiated Trials (IITs), including trial design, protocol preparation, and regulatory assistance for advancing MyD88-targeted therapies.
Types of MyD88-Targeted Diseases
- Autoimmune Diseases
- Inflammatory Diseases
- Transplant Rejection
- Ischemia-Reperfusion
- Allergic Diseases
- Cancers
- Neurodegenerative
- Metabolic Diseases
Protheragen is committed to offering a full-service tailored approach to MyD88-related diseases including monoclonal antibody development, disease model development, pharmacokinetics and drug safety evaluation. In addition, we also focus on investigator-initiated trials, which broadens the early phase development of the drug and boosts progress in antibody-based therapeutics technologies.
If you are interested in our services, please don't hesitate to contact us.
Reference
- Bayer, A. L., and P. Alcaide. "Myd88: At the Heart of Inflammatory Signaling and Cardiovascular Disease." J Mol Cell Cardiol 161 (2021): 75-85.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.